Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

Biote has announced the appointment of Komal Bajaj, MD, MS as its new Chief Medical Officer. This leadership change is part of the company's strategy to enhance its medical expertise. Dr. Bajaj brings significant experience in the biopharma sector to her new role.

Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

Biote has appointed Bob Peterson, the current Chief Financial and Chief Business Officer, as the Interim CEO. This leadership change comes as the company seeks to navigate its strategic direction. Further details regarding the transition and its implications for the company have not been disclosed.

Biote Reports First Quarter 2026 Financial Results

Biote has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance during this period. Specific details regarding revenue, expenses, and other financial metrics were not disclosed in the text provided.

Biote Schedules First Quarter 2026 Financial Results Release and Conference Call

Biote has announced the scheduling of its financial results release for the first quarter of 2026, along with a conference call to discuss these results. This event aims to provide stakeholders with insights into the company's financial performance and future outlook. Further details regarding the call will be shared closer to the date.

Transforming Healthy Aging 2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered "forward-looking statements" within the meaning of t

Biote Reports Fourth Quarter and Full Year 2025 Financial Results Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue

Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call

Biote Corp. has announced the release date for its fourth quarter and full year financial results, scheduled for March 11, 2026. A conference call will follow at 5:00 p.m. ET to discuss these results. The company emphasizes its commitment to hormone replacement therapy and healthy aging solutions, showcasing its innovative approach in the healthcare sector.

Biote Reports Third Quarter 2025 Financial Results Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 202

Biote Reports Second Quarter 2025 Financial Results Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure gro

Biote Names Rich Barrera to Board of Directors IRVING, TX

Biote Reports First Quarter 2025 Financial Results Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and bu

Biote Reports Fourth Quarter and Full Year 2024 Financial Results Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook IRVING, TX

Biote Announces CEO Retirement and Succession Plan Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company s Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Web

Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitiv

Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance IRVING, TX

Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares IRVING, TX

Biote Reports First Quarter 2024 Financial Results Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, wi

Biote Announces Definitive Settlement with Founder Company to repurchase all of Founder s 18.4 million shares at $4.17 per share IRVING, TX

Biote Reports Fourth Quarter and Full Year 2023 Financial Results Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder valu

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder s Shares Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share IRVING, TX

Biote Announces $20 Million Share Repurchase Authorization IRVING, TX

Biote Provides Preliminary 2023 Results and Initial 2024 Guidance IRVING, TX

Biote Names Robert Peterson as Chief Financial Officer IRVING, TX

Biote Reports Third Quarter 2023 Financial Results Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance IRVING, TX

Biote Reports Second Quarter 2023 Financial Results Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Well

Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX

Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance IR

Biote Reports Fourth Quarter and Full Year 2022 Financial Results Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 millio

Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX

Biote Appoints Debby Morris to Board of Directors IRVING, TX

Biote Releases Updated Corporate Presentation for October 2022

Biote Announces Approval to Relist on The Nasdaq Stock Market Company will resume trading under its existing symbols BTMD and

Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX

Biote Issues Correction to Second Quarter Operating Loss and Net Income IRVING, TX

Biote Reports Second Quarter 2022 Financial Results Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance *Revised Dial-in Information for the Conference C

BioTE Holdings, LLC Unaudited Quarterly Financial Results for 2021 biote Corp. (the Company ) is furnishing the following tables which set forth supplemental unaudited financial information of BioTE Holdings, LLC and its

BIOTE HOLDINGS, LLC CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Quarterly Period ended

Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry Business combination with Haymaker Acquisition Corp. III complete biote Corp. s common stock will trade on the Nasdaq Stock Ex

Haymaker Acquisition Corp. III Announces Stockholder Approval of Business Combination with Biote

Biote Reports First Quarter 2022 Financial Results and Provides Corporate Update Company accelerates expansion and reiterates 2022 guidance Net sales of $37 million in the quarter, an 18% increase year-over-year from the

to this Current Report on Form 8-K. Transaction costs amounted to $16,973,945, consisting of $6,000,000 of underwriting fees, $10,500,000 of deferred underwriting fees, and $473,945 of other offering costs. In addition,

THIS PROMISSORY NOTE ( NOTE ) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT ). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN TH

Andy Heyer: Welcome to the Biote corporate presentation. This is Andy Heyer from Haymaker III, and we re excited you can join us. Biote is a really dynamic consumer healthcare company, and we re really looking forward to

Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III Biote is a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization spac

Haymaker Acquisition Corp. III Announces the Separate Trading of its Class A Common Stock and Redeemable Warrants Commencing

to this Current Report on Form 8-K. Transaction costs amounted to $16,973,945, consisting of $6,000,000 of underwriting fees, $10,500,000 of deferred underwriting fees and $473,945 of Initial Public Offering costs. In ad

Haymaker Acquisition Corp. III Announces Pricing of $300 Million Initial Public Offering